| Literature DB >> 9185706 |
E Corey1, S K Wegner, J E Stray, M J Corey, E W Arfman, P H Lange, R L Vessella.
Abstract
While prostate-specific antigen (PSA) is already an invaluable marker for prostate cancer, there is continuing demand for new anti-PSA antibodies with specific characteristics, e.g., high sensitivity and specificity and equimolar binding to free PSA (f-PSA) and the PSA-alpha-1-antichymotrypsin complex (PSA-ACT), as well as the ability to distinguish between these 2 immunoreactive forms of PSA. We have therefore generated and characterized 10 anti-PSA monoclonal antibodies (MAbs). Apparent dissociation constants (Kd) of MAbs were determined by direct ELISA yielding Kd-0.2-164.0 nM. Western blots suggested that 3 of the MAbs (60-1A2, 60-8A2 and 17-1A2) bind to linear epitopes. Sandwich assays identified 5 major antigenic regions as binding targets of the MAbs. Three combinations of MAbs recognize f-PSA and PSA-ACT in equimolar fashion with high sensitivity. Two of the MAb combinations are specific for f-PSA. Physical analysis of the new antibodies has allowed us to assign the MAbs to binding classes (based on their sandwiching capabilities) and to determine accurate apparent dissociation constants.Entities:
Mesh:
Substances:
Year: 1997 PMID: 9185706 DOI: 10.1002/(sici)1097-0215(19970611)71:6<1019::aid-ijc18>3.0.co;2-8
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396